Business

Assertio Therapeutics merges with Zyla Life Sciences

Posted March 19, 2020 1:00 am

LAKE FOREST - Assertio Therapeutics announced Wednesday it will merge with Pennsylvania-based Zyla Life Sciences, creating a new commercial pharmaceutical company with neurology, inflammation and pain products.

Terms of the all-stock deal were not disclosed.

The new company will retain the Assertio name and will have a portfolio of branded nonsteroidal anti-inflammatory drugs commonly used by neurologists, orthopedic surgeons, internists, women's health providers, podiatrists and pain care specialists. Assertio's portfolio includes the migraine drug Cambia, shingles drugs Gralise and pain reliever Zipsor.

Assertio President and CEO Arthur Higgins will become nonexecutive chairman of the new company and Zyla CEO and Director Todd Smith will become president and CEO.

The deal is expected to close in the second quarter of 2020, officials said,

Article Comments

Article Categories
Business Communities Health Care Lake Forest

Article Comments

Guidelines: Keep it civil and on topic; no profanity, vulgarity, slurs or personal attacks. People who harass others or joke about tragedies will be blocked. If a comment violates these standards or our terms of service, click the "flag" link in the lower-right corner of the comment box. To find our more, read our FAQ.